Section
The phase 2 MIRA trial shows sonelokimab, an IL-17A/F-inhibiting nanobody, significantly improves outcomes in moderate-to-severe hidradenitis suppurativa with good tolerability compared to placebo.
A large UK study reveals that over two-thirds of biologic-eligible severe asthma patients improve without biologic therapy, identifying distinct exacerbation trajectories linked to blood eosinophil levels and disease phenotype.
This multicenter retrospective study identifies key baseline predictors influencing short-term remission and relapse in pemphigus patients treated with rituximab plus glucocorticoids, guiding personalized treatment strategies.
The PORTOLA phase 2a trial evaluates zetomipzomib, a selective immunoproteasome inhibitor, demonstrating numerically improved biochemical remission and steroid-sparing effects in autoimmune hepatitis patients with inadequate response to sta
Dupilumab treatment in moderate to severe asthma significantly reduces mucus plug burden, resolves existing plugs, limits new plug formation, and decreases plug radiodensity on CT scans, correlating with improved lung function and ventilati
This study reveals that TL1A-activated CD4+ T cells drive distinct cellular and molecular changes in the rectal mucosa of Crohn’s disease patients with perianal fistulising disease (PFD), highlighting a novel TL1A-LTα1β2/IL-22 axis in
This article reviews exploratory analyses from a phase 2b trial examining eosinophil count changes in adults with uncontrolled moderate-to-severe asthma treated with the IL-4Rα inhibitor rademikibart, indicating a low risk of treatment-emer
The PASSAGE phase 4 study reveals tezepelumab significantly reduces exacerbation rates and improves lung function and quality of life in a broad US severe asthma population, including underrepresented groups and varied phenotypes.
This study reveals that genetic risk factors and immune pathways differ significantly between type 1 diabetes patients stratified by HLA-DR3 and HLA-DR4 status, providing insights into disease heterogeneity and personalized risk mechanisms.
This study reveals distinct clinical associations of IL-12p40 and IL-18 in severe fibrosing chronic graft-versus-host disease, highlighting their differing impacts on relapse risk, survival, and immune responses post-allogeneic stem cell tr
This study reveals that central serous chorioretinopathy (CSCR) in patients with immune-mediated disorders exhibits distinct clinical and imaging features, with immune-mediated status linked to poorer visual outcomes and higher recurrence,
Single-cell multi-omics profiling reveals novel immune signatures linked to coronary artery disease and cardiovascular outcomes, independent of traditional inflammatory markers, offering new avenues for risk stratification and personalized
Autoimmune conditions in acute interstitial pneumonia (AIP) are associated with reduced 90-day mortality and better discharge outcomes, indicating distinct clinical trajectories and opportunities for tailored care.
Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.
Meconium aspiration syndrome (MAS) significantly increases the risk of preschool asthma and bronchiolitis by disrupting neonatal airway development, highlighting the need for early respiratory monitoring and intervention strategies.
The MINT trial demonstrates that inebilizumab markedly lowers exacerbation rates and rescue therapy use in AChR+ and MuSK+ generalized myasthenia gravis patients undergoing corticosteroid tapering.
Reflectance confocal microscopy features at week 4 post-dupilumab treatment, combined with deep learning analysis, enable non-invasive prediction of therapeutic response in facial atopic dermatitis patients.
A multicenter randomized trial found that initiating a 1-hour resuscitation bundle including early antibiotics, fluids, vasopressors, and hydrocortisone in the prehospital setting did not significantly reduce 28-day mortality in adults with
Severe trauma induces maturation and cytotoxic phenotypes in NK cells but paradoxically decreases expression of activating receptors critical for immune defense, revealing a mechanism underlying posttrauma immune dysregulation and vulnerabi
Severe trauma induces phenotypic maturation of natural killer cells but leads to a loss of key activating receptors, potentially driving posttraumatic immune dysfunction and increased infection risk.
